Cetirizine vs Astemizole in the Treatment of Chronic Idiopathic Urticaria

Alomar, A.; Cuadra, J. de la; Fernandez, J. Fraga

doi:10.1177/030006059001800503

Cited by 29 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results confirm those of another study which noted rapid clinical improvement in recipients of cetirizine, as compared with those receiving astemizole (27). This difference in onset of action was also significant in another instance (28).…”

mentioning

confidence: 67%

Clinical studies with cetirizine in allergic rhinitis and chronic urticaria

Broide

1995

Allergy

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 67%

Clinical studies with cetirizine in allergic rhinitis and chronic urticaria

Broide

1995

Allergy

View full text Add to dashboard Cite

show abstract

“…Cetirizine is a metabolite of hydroxyzine which has recently been demonstrated as effective in the management of allergic disorders, including chronic idiopathic urticaria (Alomar et al, 1990) and allergic rhinitis (Backhouse et al, 1990). However, the precise mechanisms underlying its beneficial effect remain unknown.…”

Section: Methodsmentioning

confidence: 99%

The effect of cetirizine on antigen‐dependent leucopenia in the guinea‐pig

Coyle

Lefort

Vargäftig

1991

British J Pharmacology

View full text Add to dashboard Cite

Intravenous administration of ovalbumin (1 mg kg−1) to guinea‐pigs that had previously been injected with 3.5 × 109 platelets from actively sensitized animals induced an approximately 40% decrease in the number of circulating leucocytes 30–60 min later, whereas the number of platelets was not affected. In contrast, there was no change in the leucocyte number following antigen challenge of guinea‐pigs that had received platelets from non‐immunised animals. This platelet‐dependent leucopenia was inhibited by prior treatment of the recipient animal with cetirizine (10–30 mg kg−1, i.v.). Terfenadine (50 mg kg−1, p.o.) and mepyramine (2 mg kg−1, i.v.) were completely inactive in this respect. All doses of anti‐histamines were used at concentrations which completely inhibited the bronchoconstriction to an i.v. injection of 5 μg kg−1 of histamine. The site of action of cetirizine is most likely to be the platelet as leucopenia induced by the neutrophil agonists leukotriene B4 (LTB4) (30 ng kg−1) and platelet activating factor (PAF) (30 ng kg−1) were not modified by cetirizine treatment. In these experiments, we failed to support a role for lipoxygenase products as mediators of the platelet‐dependent leucopenia, as the selective lipoxygenase inhibitor BWA4C (50 mg kg−1, p.o.) was ineffective. Our present results confirm and extend previous data demonstrating that antigen stimulated platelets can induce leucopenia in non‐immunised animals and this can be inhibited by the anti‐allergic agent, cetirizine, by an action which is probably unrelated to its anti‐histamine properties. The precise nature of the platelet derived factor(s) and their target of action remains to be determined.

show abstract

“…In two studies, astemizole was slightly more effective than terfenadine at the doses chosen for the treatment of urticaria (18,26). In one comparative study of astemizole and cetirizine, cetirizine was superior to astemizole in the treatment of chronic idiopathic urticaria (27). In another evaluation, astemizole was similar to cetirizine for chronic urticaria, however, the clinical benefit occurred significantly more rapidly with cetirizine (28).…”

Section: Clinical Studiesmentioning

confidence: 99%

“…A trial comparing the efficacy of cetirizine and astemizole in chronic urticaria demonstrated similar efficacy of the two agents, but with cetirizine acting more rapidly than astemizole (28). Another similar trial demonstrated superior efficacy of cetirizine in reduction of wheal size compared to astemizole (27). Daily dosing of 10 mg cetirizine has been shown to be more efficacious than 60 mg terfenadine twice a day in the treatment of chronic urticaria (37).…”

Section: Clinical Studiesmentioning

confidence: 99%

Second‐ and third‐generation antihistamines in the treatment of urticaria

Ellis

Day

2000

Dermatologic Therapy

View full text Add to dashboard Cite

Chronic urticaria is mainly idiopathic in nature and can be difficult to treat. While less responsive to antihistamine therapy than acute urticaria, antihistamines still play a key role in the management of symptomatology. While many of the antihistamines still commonly used to treat urticaria are first generation H1 antagonists (e.g., diphenhydramine, hydroxyzine), the more recently developed second‐generation agents (e.g., loratadine, cetirizine) and their metabolites—the third‐generation antihistamines (e.g., fexofenadine, norastemizole, descarboxyloratadine)—possess many of the desirable clinical effects of the first‐generation agents with a more tolerable side effect profile. This review discusses the advantages and disadvantages of each of the various second‐ and third‐generation agents available, and presents some of the data showing the differences among these agents in the treatment of chronic urticaria.

show abstract

Cetirizine vs Astemizole in the Treatment of Chronic Idiopathic Urticaria

Cited by 29 publications

References 7 publications

Clinical studies with cetirizine in allergic rhinitis and chronic urticaria

Clinical studies with cetirizine in allergic rhinitis and chronic urticaria

The effect of cetirizine on antigen‐dependent leucopenia in the guinea‐pig

Second‐ and third‐generation antihistamines in the treatment of urticaria

Contact Info

Product

Resources

About